Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
6
×
boston blog main
fda
6
×
life sciences
national blog main
boston top stories
clinical trials
national top stories
alnylam pharmaceuticals
drugs
new york blog main
new york top stories
onpattro
patisiran
san francisco blog main
akcea therapeutics
biotech
deals
european medicines agency
hereditary transthyretin amyloidosis
inotersen
investing
pfizer
rna interference
san diego blog main
san diego top stories
san francisco top stories
tafamidis
acute hepatic porphyrias
akin akinc
akouos
allopregnanolone
aminolevulinic acid
andrew fire
astellas pharmaceuticals
avapritinib
blueprint medicines
brexanolone
california institute for biomedical research
craig mello
What
drug
6
×
fda
6
×
medicine
alnylam
approved
rnai
approval
interference
medicines
pharmaceuticals
rna
specifically
affects
afternoon
ago
alnylam’s
americans
approves
blueprint
brexanolone
cancer
candidate
cells
currently
date
depression
devastating
developing
disorder
ema
employ
europe
fast
follows
frequency
gene
gets
harmful
hearing
history
Language
unset
Current search:
boston
×
fda
×
drug
×
fda
×
@xconomy.com
4 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
5 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
6 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
6 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug